Pemphigoid disease model systems for clinical translation

Marvin Tigges ¹ Sören Dräger ² Ilaria Piccini ¹ Katja Bieber ² Artem Vorobyev ² Janin Edelkamp ¹ Marta Bertolini ¹ Ralf J Ludwig ^2*

• ¹ QIMA Life Sciences, QIMA Monasterium, Münster, Germany
• ² Department of Dermatology, University of Lübeck, Lübeck, Germany

Pemphigoid diseases constitute a group of organ-specific autoimmune diseases characterized and caused by autoantibodies targeting autoantigens expressed in the skin and mucous membranes. Current therapeutic options are still based on unspecific immunosuppression that is associated with severe adverse events. Biologics, targeting the IL4-pathway or IgE are expected to change the treatment landscape of pemphigoid diseases. However, clinical studies demonstrated that targeting these pathways alone is most likely not sufficient to meet patient and healthcare partitioners expectations.Hence, model systems are needed to identify and validate novel therapeutic targets in pemphigoid diseases. These include pre-clinical animal models, in vitro and ex vivo model systems, hypothesis-driven drug repurposing, as well as exploitation of realworld-data. In this review, we will highlight the medical need for pemphigoid diseases, and in-depth discuss the advantages and disadvantages of the available pemphigoid disease model systems. Ultimately, we discuss how rapid translation can be achieved for the benefit of the patients.